Pod Insights Finshots Daily Risdiplam raises questions about pharma's ethics About this episode In today’s episode on April 1st 2025, we discuss the economics of Risdiplam and why a pharma battle around the drug raises concerns about the industry’s ethics. Speak to Ditto's advisors now, by clicking the link here - https://ditto.sh/9zoz41
Transcript 0:00 Speaker 00 Hello folks, you're listening to Finshots Daily. And in today's episode, we discuss the economics of risdiplam and why a pharma battle around the drug raises concerns about the industry's ethics.
0:13 Speaker 00 Before we start today's episode, here's a quick announcement from Team Ditto. Did you know that 83% of Indian households are put in grave financial danger if the breadwinner passes away? This is why it's important to be financially prudent and buy a term insurance. If you're young, you can secure your family with a cover of over one crore at nominal premiums of just 10 to 15K a year. At Ditto Insurance, a product by Finshots, we've helped thousands of people select a term plan with the help of certified advisors. We promise a spam-free experience, no pressure to buy, and a claim support team always by your side. Head over to the link in the description or Google Ditto Insurance to speak to an expert now.
0:59 Speaker 00 Now, on to today's episode. Let's start today's story with a sensitive hypothetical situation. Imagine someone in India suffering from a rare genetic disease and for years, there has been no cure. But one day, like magic, a foreign pharmaceutical company develops a breakthrough treatment. It patents the drug and begins selling it in India. But here's the catch, the medicine costs a bomb. Unable to afford it, the patient slowly suffers and eventually passes away. What you just read, dear folks, isn't an imaginary example or an isolated one. It's the reality for one in 7,700 people born in India. In fact, as you read this, around 4,000 Indians are battling spinal muscular atrophy, or SMA, a rare genetic disorder that affects the nerves.
1:45 Speaker 00 For the uninitiated, the normal human body needs a protein called SMN, survival motor neuron, to perform basic functions like moving, swallowing, and even breathing. But in SMA patients, the body doesn't produce enough of it, leading to a lifetime of struggle. And since diseases don't discriminate based on financial status, many patients never get the treatment they need. That said, SMA is the leading genetic cause of infant deaths in India. What's even worse is that one in 38 people unknowingly carry the faulty gene responsible for it. In 2021 though, a ray of hope emerged. A drug called Risdiplam, sold as Everest D by Swiss farm giant F. Hoffmann La Roche AG. We'll just call it Roche from here on.
2:29 Speaker 00 It helped SMA patients produce more of the SMN protein, allowing them to manage their conditions better, even if it wasn't a complete cure. The only problem? A year's supply of Everest D costs anywhere between 20 lakh rupees and 70 lakh rupees. That's because each bottle is priced at around 2 lakh rupees and patients need at least 30 bottles annually to effectively manage their condition. While that's cheaper than alternatives like Zorganswa, a gene therapy which costs staggering 17 crore rupees, or even Nusinerson, a drug priced at 87 lakh rupees. Everest D is still the most affordable option, yet out of reach for most. That's what Natco Pharma, an Indian company, wanted to change. It wanted to manufacture Risdiplam at a fraction of the cost to make it accessible.
3:14 Speaker 00 But, maybe you've already guessed that this didn't sit well with Roche. After all, its patent for Risdiplam is valid until May 2035, meaning no one else can manufacture it commercially without permission. Natco however, went ahead anyway, so Roche dragged it to court, asking to block what it saw as a patent violation. But, here's the twist. A few days ago, the Delhi High Court refused to block Natco from launching its own version of the drug. In the court's own words, "The approved drug, that is Risdiplam, which is marketed under the name Everest D, is not available at reasonably affordable prices in India." Thus, if a party is able to manufacture the drug and make it available at an affordable
3:56 Speaker 00 price, in such a case, the public interest would have to outweigh the need for grant of injunction. At this point, you're probably thinking, "But hey, isn't this unfair to companies that invest millions in researching and developing lifesaving drugs?" And you wouldn't be wrong, but then, you have to understand why Roche couldn't fully stop Natco from baking into the market. See, pharma companies spend years researching and developing new treatments, pouring in enormous sums of money to find a cure. So, when they finally succeed, they safeguard their innovation fiercely and price their drugs high to recover those massive R and D costs. That's exactly why Everest D comes with such a hefty price tag. On top of that, the market for the drug is tiny.
4:40 Speaker 00 Only a handful of people need it. So, Roche prices it steeply, trying to maximize profits before its patent expires. Because once a generic drug maker steps in, the monopoly vanishes and so do these sky-high profits. But, look at the economics of Risti Plam and you'll see why Roche's case isn't as strong. The actual cost of producing a bottle of Everest D, including active ingredients, packaging, and even a 20% profit margin could be as low as 3,000 rupees. Even if Roche added a whopping 1,000% profit margin, it could still sell the drug in India at a 99% discount to its US price, that is 11,170 dollars or roughly 9.5 lakh rupees per bottle.
5:23 Speaker 00 And that exactly raises ethical concerns. Is Roche making a fair profit or is it exploiting desperate patients? Then, there's the larger debate about patent laws and access to medicines in India. Before 1970, India only granted patents on the process of making a drug, not the drug itself. This allowed Indian pharma companies to reverse engineer and produce affordable generic medicines. Those are copied versions. That's also how India became the pharmacy of the world, supplying low-cost medicines globally. But, things changed in 1995, when India signed the TRIPS agreement, that is Trade Related Aspects of Intellectual Property Rights, under the WTO. By 2005, Indian patent laws were put at par with global standards.
6:07 Speaker 00 Meaning, companies could no longer manufacture or sell patented drugs for 20 years without the patent holder's consent. But then TRIPS also included exceptions known as TRIPS flexibilities. These ensure that public health isn't compromised, especially when it comes to affordable medicines. And here are three key ones that matter. Number one, Compulsory licensing. In cases where a patented drug is either too expensive or fails to meet public demand, pharma companies can legally manufacture a generic version without the patent holder's consent. This was seen in the 2013 Natco Pharma versus Bayer Corporation case, where Natco was granted permission to produce a more affordable version of Bayer's cancer drug. Number two, no patent evergreening.
6:51 Speaker 00 Pharma giants can't extend a patent's life by making minor tweaks to a drug, unless they prove that the change has significantly improved its efficacy. This prevents companies from holding on to patents indefinitely and blocking generic alternatives. A good example is the 2013 Novartis case, where the company tried to extend its patent on Glivek, an anti-cancer drug, but was denied. Number three, parallel imports. If a drug costs hundred dollars in Sweden, but sells for two hundred dollars in India, Indian pharma companies or even the government can import the cheaper version without the patent holder's approval. This ensures that life-saving drugs aren't priced out of reach simply because of geography.
7:32 Speaker 00 These flexibilities exist to strike a balance so that pharma companies get due credit for their innovation, but life-saving treatments don't remain exclusive only to those who can afford them. And as we explained earlier, the court outweighed these factors in the Roche versus Natco case and sided with the public interest. It acknowledged that EVERSD was financially out of reach for most SMA patients and also caught Roche trying to unfairly extend its monopoly by using an unfair tactic called evergreening. Evergreening, or forever patenting, is when companies extend their patent rights by filing a new patent on an existing drug after making minor tweaks without actually improving its effectiveness.
8:13 Speaker 00 The court saw through this because Roche's own patent filings in the US, Australia and Canada suggested that EVERSD plan was already part of an earlier patent. And if Roche had filed for the original patent in India, it would have expired much sooner. And finally, there's India's Patent Act of 2005, which gives the government the power to step in and allow generic drug production when it's in the public's best interest. So, when the court refused to rule in Roche's favour, it wasn't about India undervaluing patents, it was about ethics. It was about whether foreign pharma giants should be allowed to squeeze Indian markets dry while leaving little room for Indian companies to step in. Of course, global pharmas don't see it that way,
8:55 Speaker 00 because companies like Novartis have already voiced concerns over India's patent laws, even shifting research centres to Singapore and China, fearing their intellectual property isn't safer. They argue that India isn't letting them innovate. But here's the real question: Are they innovating for the greater good or are they just running businesses designed to squeeze abnormal profits out of vulnerable people? We'll leave you with that thought, but before you go, you should also know that Roche isn't out of options yet. It can still appeal the Delhi High Court's decision and if it wins, it could claim damages too. So, until the case reaches a final verdict, the court has put the brakes on Natco's plan to roll out its generic version of RISD plan.
9:41 Speaker 00 Thank you for listening to today's episode. And if you want to share your feedback or suggestions, do drop us an email to [email protected] . Until next time.
Previous OpenAI's new AI model just made everyone a designer overnight Next Why Warren Buffett isn't a fan of gold Page updated November 11, 2026 · transcript and summary are machine-generated